Physician profile
Ingrid Herskovitz
NPI 1366869562
$6,075.18
in general payments reported to CMS, 2019-2025
31 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $56.72 · 2021: $242 · 2022: $934 · 2023: $810 · 2024: $1,577 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,251.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.70 | 2019-2025 | |
| Genzyme Corporation | $815.55 | 2019-2025 | |
| Incyte Corporation | $592.63 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $534.30 | 2021-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $470.20 | 2019-2025 | Dupixent |
| Pfizer INC. | $331.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $256.91 | 2022-2025 | |
| Janssen Biotech, INC. | $233.49 | 2021-2024 | Tremfya |
| Allergan, INC. | $228.98 | 2019 | |
| Almirall LLC | $199.02 | 2022-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $188.43 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Leo Pharma INC. | $186.61 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $168.08 | 2021-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $156.13 | 2023-2025 | Zoryve |
| Ucb, INC. | $107.18 | 2022-2025 | Bimzelx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.85 | 2023-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Mayne Pharma Commercial LLC | $65.76 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.08 | 2024-2025 | Spevigo |
| Krystal Biotech INC | $47.10 | 2023 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $45.28 | 2023-2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $34.33 | 2024 | Sotyktu |
| Biofrontera INC. | $31.22 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $24.80 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.37 | 2025 | Cabtreo |
| Solta Medical, A Division of Bausch Health US, LLC | $20.94 | 2024 | Clear+Brilliant |
| Kyowa Kirin, INC. | $20.44 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.44 | 2022 | |
| Biomarin Pharmaceutical INC. | $17.36 | 2022 | |
| Ascendis Pharma Endocrinology INC | $15.94 | 2023 | |
| Organon LLC | $12.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Herskovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.